SOD1 and amyotrophic lateral sclerosis: Silencing of mutant SOD1, C9orf72 or FUS genes in pre-clinical models with cerebrospinal fluid delivered antisense oligonucleotides (ASO) or virally delivered shRNAs have demonstrated the validity of those approaches as a potential therapy in ALS patients [123].